Patent ID: 11857565
Assignee: SEAGEN INC.
Field: Pharmaceuticals (Chemistry)
Classification: CPC C  A | IPC A

Claim 7:
8. The Ligand Drug Conjugate compound of claim 1, wherein:
(a) each drug linker moiety is represented by the structure of:, or a salt thereof, wherein
HE is an optional Hydrolysis Enhancing Unit, which is a component provided by A or a first subunit thereof;
AO is an optional second subunit of A;
A′ is a second optional Stretcher Unit;
subscript a′ is 0 or 1, indicating the absence or presence of A′, respectively;
R34 is —CH3, —C(CH3)2, —CH2COOH, —CH2CH2COOH, or —CH2CH2CH2CH2NH2;
R35 is methyl, isopropyl, —CH2C(═O)NH2, —CH2COOH, —CH2CH2C(═O)NH2, —CH2CH2COOH, —CH2CH2CH2NHC(═NH)NH2, —CH2CH2CH2NH2, —CH2CH2CH2NH—C(═O)CH3, —CH2CH2CH2NH—C(═O)H, —CH2CH2CH2CH2NHC(═NH)NH2, —CH2CH2CH2CH2NH2—, —CH2CH2CH2CH2NH—C(═O)CH3, —CH2CH2CH2CH2NH—C(═O)H, —CH2CH2CH2NHC(═O)NH2, —CH2CH2CH2CH2NHC(═O)NH2, or —CH2CH2CH(OH)CH2NH2;
R2 is methyl; and
R1 is C1-C9 alkyl, or
R1 is (C3-C6 carbocyclyl)-alkylene- of up to 9 total carbon atoms, or
R1 is —(C2-C6 alkylene)-X—R4, wherein X is an amide or carbamate functional group and R4 is C1-C6 alkyl,
with the proviso that the total number of carbon atoms in R2 and the (carbocyclyl)alkyl(ene) moiety of R1 is between 4 and 10, and R1 is not methyl, or
(b) each drug linker moiety is represented by the structure of:, or a salt thereof, wherein
AO is absent or an α-amino acid or a β-amino acid residue;
A′ is present substituted or unsubstituted C2-C6 alkylene diamine residue;
R34 is —CH2CO2H or —CH2CH2CO2H;
R2 is methyl; and
R1 is C1-C9 alkyl, or
R1 is (C3-C6 carbocyclyl)-alkylene- of up to 9 total carbon atoms, or
R1 is —(C2-C6 alkylene)-X—R4, wherein X is an amide or carbamate functional group and R4 is C1-C6 alkyl,
with the proviso that the total number of carbon atoms in R2 and the (carbocyclyl)alkyl(ene) moiety of R1 is between 4 and 10, and R1 is not methyl, or
(c) each drug linker moiety is represented by the structure of:, or a salt thereof, wherein
AO is absent or is an α-amino acid or a β-amino acid residue; and
R1 is C1-C9 alkyl, or
R1 is (C3-C6 carbocyclyl)-alkylene- of up to 9 total carbon atoms, or
R1 is —(C2-C6 alkylene)-X—R4, wherein X is an amide or carbamate functional group and R4 is C1-C6 alkyl,
with the proviso that the total number of carbon atoms in R2 and the (carbocyclyl)alkyl(ene) moiety of R1 is between 4 and 10, and R1 is not methyl, or
(d) each drug linker moiety is represented by the structure of:, or a salt thereof, wherein
Ra3 is hydrogen, —CH3, or —CH2CH3, wherein the secondary or tertiary amine so defined is optionally protonated as an acid addition salt form;
AO is absent or is an α-amino acid or a β-amino acid residue;
A′ is a substituted or unsubstituted C2-C6 alkylene diamine residue
R34 is —CH2CO2H or —CH2CH2CO2H;
R2 is methyl; and
R1 is C1-C9 alkyl, or
R is (C3-C6 carbocyclyl)-alkylene- of up to 9 total carbon atoms, or
R1 is —(C2-C6 alkylene)-X—R4, wherein X is an amide or carbamate functional group and R4 is C1-C6 alkyl,
with the proviso that the total number of carbon atoms in R2 and the (carbocyclyl)alkyl(ene) moiety of R1 is between 4 and 10, and R1 is not methyl, or
(e)each drug linker moiety is represented by the structure of, or a salt thereof, wherein
AO is absent or is an α-amino acid or a β-amino acid residue; and
R1 is C1-C9 alkyl, or
R1 is (C3-C6 carbocyclyl)-alkylene- of up to 9 total carbon atoms, or
R1 is —(C2-C6 alkylene)-X—R4, wherein X is an amide or carbamate functional group and R4 is C1-C6 alkyl,
with the proviso that the total number of carbon atoms in R2 and the (carbocyclyl)alkyl(ene) moiety of R1 is between 4 and 10, and R1 is not methyl,
or
(f) each drug linker moiety is represented by the structure of:, or a salt thereof, wherein
Ra3 is hydrogen, —CH3, or —CH2CH3, wherein the primary or secondary amine so defined is optionally protonated as an acid addition salt form;
AO is absent or is an α-amino acid or a β-amino acid residue;
A′ is substituted or unsubstituted C2-C6 alkylene diamine residue
R34 is —CH2CO2H or —CH2CH2CO2H;
R2 is methyl; and
R1 is C1-C9 alkyl, or
R1 is (C3-C6 carbocyclyl)-alkylene- of up to 9 total carbon atoms, or
R1 is —(C2-C6 alkylene)-X—R4, wherein X is an amide or carbamate functional group and R4 is C1-C6 alkyl,
with the proviso that the total number of carbon atoms in R2 and the (carbocyclyl)alkyl(ene) moiety of R1 is between 4 and 10, and R1 is not methyl, or
(g) each drug linker moiety is represented by the structure of:, or a salt thereof, wherein
AO is absent or is an α-amino acid or a β-amino acid residue; and
R1 is C1-C9 alkyl, or
R1 is (C3-C6 carbocyclyl)-alkylene- of up to 9 total carbon atoms, or
R1 is —(C2-C6 alkylene)-X—R4, wherein X is an amide or carbamate functional group and R4 is C1-C6 alkyl,
with the proviso that the total number of carbon atoms in R2 and the (carbocyclyl)alkyl(ene) moiety of R1 is between 4 and 10, and R1 is not methyl.